-
Case Report
-
Korean J Med. 2014;87(2):224-228. Published online August 1, 2014.
DOI: https://doi.org/10.3904/kjm.2014.87.2.224
- 일차성 중추신경계 림프종의 경막 내 Rituximab 치료 2예
-
장용호, 하태환, 김덕희, 김성록, 유영진, 손병석, 이혜란
-
1인제대학교 의과대학 상계백병원 내과
2인제대학교 의과대학 일산백병원 내과
- Two Cases of Treatment with Intrathecal Rituximab for Primary Central Nervous System Lymphoma
-
Yong Ho Jang, Tae Hwan Ha, Deok Hee Kim, Sung Rok Kim, Young Jin Yuh, Byeong Seok Sohn, Hye Ran Lee
-
1Department of Internal Medicine, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea
2Department of Internal Medicine, Ilsan Paik Hospital, Inje University College of Medicine, Seoul, Korea
- Corresponding author: Young Jin Yuh ,Tel: +82-2-950-1114, Fax: +82-2-950-1429, Email: yjyuh@paik.ac.kr
- Received: August 12, 2013; Revised: October 1, 2013 Accepted: October 30, 2013.
-
߽ɾ :일차성 중추신경계 림프종; 경막 내 항암화학요법; Rituximab; 림프종 수막염
- Abstract
- Primary central nervous system lymphoma (PCNSL) is an aggressive non-Hodgkin’s lymphoma (NHL), usually composed of diffuse large B-cells. Although rituximab is known for its curative effect on B-cell NHL, data on the use of intrathecal rituximab for PCNSL are limited. In this report, we present two patients showing relapsed PCNSL with lymphomatous meningitis. Both patients were refractory to conventional methotrexate-based intrathecal chemotherapy. However, after intrathecal rituximab with or without conventional intrathecal chemotherapy, both patients showed stable disease on magnetic resonance brain imaging and cerebrospinal fluid analysis. There were no serious adverse events during each of 3 and 6 cycles with intrathecal rituximab immunotherapy.
Keywords :Primary CNS lymphoma, Intrathecal immunotherapy, Rituximab, Lymphomatous meningitis
